Watchword: getting the younger generations talking about art. Following on from the success of the Menarini Pills of Art, with 18 million views worldwide, Menarini now launches the ‘junior’ version, in which young art experts reply to the questions, and sometimes unexpected curiosities, children may have on the great works of the Italian Renaissance. A more fun way to see art that the great masters themselves would have approved!

Florence (Italy) November 4th, 2021 – The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML). SEL24/MEN1703 is a first-in-class, orally available, dual PIM/FLT3 inhibitor, in-licensed by Menarini from Ryvu Therapeutics, and currently investigated in the DIAMOND-01 trial as a single agent for the treatment of patients with relapsed/refractory AML.

Florence, Italy and Boston, Mass., October 20, 2021 – the Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced positive topline results from the EMERALD study.

• The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN
• If approved by the European Commission, ELZONRIS will be the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe